Qiaoyi Zhang

Summary

Affiliation: Merck Research Laboratories
Country: USA

Publications

  1. doi Time to treatment initiation with oral antihyperglycaemic therapy in US patients with newly diagnosed type 2 diabetes
    Q Zhang
    Merck Sharp and Dohme Corp, Whitehouse Station, NJ 08889, USA
    Diabetes Obes Metab 14:149-54. 2012
  2. pmc Assessment of severity and frequency of self-reported hypoglycemia on quality of life in patients with type 2 diabetes treated with oral antihyperglycemic agents: A survey study
    Elizabeth Marrett
    Global Health Outcomes, Merck Sharp and Dohme, Corp, Whitehouse Station, NJ, USA
    BMC Res Notes 4:251. 2011
  3. pmc Reasons given by general practitioners for non-treatment decisions in younger and older patients with newly diagnosed type 2 diabetes mellitus in the United Kingdom: a survey study
    Qiaoyi Zhang
    Merck Sharp and Dohme Corp, Whitehouse Station, NJ USA
    BMC Endocr Disord 11:17. 2011
  4. ncbi Baseline characteristic differences between patients prescribed sitagliptin vs. other oral antihyperglycemic agents: analysis of a US electronic medical record database
    Qiaoyi Zhang
    Merck Sharp and Dohme Corp, Global Health Outcomes, Whitehouse Station, NJ 08889 0100, USA
    Curr Med Res Opin 26:1697-703. 2010
  5. doi Association between hypoglycemia and inpatient mortality and length of hospital stay in hospitalized, insulin-treated patients
    Kimberly G Brodovicz
    Merck Sharp and Dohme Corp, Whitehouse Station, NJ, USA
    Curr Med Res Opin 29:101-7. 2013
  6. ncbi Compliance and persistence with concomitant statin and oral antihyperglycemic therapy
    Qiaoyi Zhang
    Global Health Outcomes, Merck Sharp and Dohme Corp, Whitehouse Station, NJ 08889, USA
    Am J Manag Care 17:746-52. 2011
  7. ncbi Differences in baseline characteristics between patients prescribed sitagliptin versus exenatide based on a US electronic medical record database
    Qiaoyi Zhang
    Global Health Outcomes, Merck Sharp and Dohme Corp, One Merck Drive, Whitehouse Station, NJ 08889 0100, USA
    Adv Ther 27:223-32. 2010
  8. ncbi Treatment and outcomes in patients with asthma and allergic rhinitis in the United kingdom
    Qiaoyi Zhang
    Merck and Co, Whitehouse Station, NJ 08889 0100, USA
    Int Arch Allergy Immunol 142:318-28. 2007
  9. doi Glycemic effectiveness and medication adherence with fixed-dose combination or coadministered dual therapy of antihyperglycemic regimens: a meta-analysis
    Steven Han
    Merck Sharp and Dohme Corp, Whitehouse Station, NJ, USA
    Curr Med Res Opin 28:969-77. 2012
  10. pmc Physician reasons for nonpharmacologic treatment of hyperglycemia in older patients newly diagnosed with type 2 diabetes mellitus
    Elizabeth Marrett
    Global Health Outcomes, WS2E85, 1 Merck Drive, Whitehouse Station, NJ, 08889, USA
    Diabetes Ther 3:5. 2012

Detail Information

Publications13

  1. doi Time to treatment initiation with oral antihyperglycaemic therapy in US patients with newly diagnosed type 2 diabetes
    Q Zhang
    Merck Sharp and Dohme Corp, Whitehouse Station, NJ 08889, USA
    Diabetes Obes Metab 14:149-54. 2012
    ..To compare the time from initial diagnosis to initiation with oral antihyperglycaemic treatment in younger versus older patients with type 2 diabetes, and to evaluate factors associated with initiating treatment...
  2. pmc Assessment of severity and frequency of self-reported hypoglycemia on quality of life in patients with type 2 diabetes treated with oral antihyperglycemic agents: A survey study
    Elizabeth Marrett
    Global Health Outcomes, Merck Sharp and Dohme, Corp, Whitehouse Station, NJ, USA
    BMC Res Notes 4:251. 2011
    ..abstract:..
  3. pmc Reasons given by general practitioners for non-treatment decisions in younger and older patients with newly diagnosed type 2 diabetes mellitus in the United Kingdom: a survey study
    Qiaoyi Zhang
    Merck Sharp and Dohme Corp, Whitehouse Station, NJ USA
    BMC Endocr Disord 11:17. 2011
    ..abstract:..
  4. ncbi Baseline characteristic differences between patients prescribed sitagliptin vs. other oral antihyperglycemic agents: analysis of a US electronic medical record database
    Qiaoyi Zhang
    Merck Sharp and Dohme Corp, Global Health Outcomes, Whitehouse Station, NJ 08889 0100, USA
    Curr Med Res Opin 26:1697-703. 2010
    ....
  5. doi Association between hypoglycemia and inpatient mortality and length of hospital stay in hospitalized, insulin-treated patients
    Kimberly G Brodovicz
    Merck Sharp and Dohme Corp, Whitehouse Station, NJ, USA
    Curr Med Res Opin 29:101-7. 2013
    ..To assess the impact of hypoglycemia on clinical outcomes among hospitalized, insulin-treated patients...
  6. ncbi Compliance and persistence with concomitant statin and oral antihyperglycemic therapy
    Qiaoyi Zhang
    Global Health Outcomes, Merck Sharp and Dohme Corp, Whitehouse Station, NJ 08889, USA
    Am J Manag Care 17:746-52. 2011
    ..To compare compliance and persistence with statin and oral antihyperglycemic therapies in patients with type 2 diabetes who received concomitant therapy. Study Design: Retrospective cohort study using a large US commercial claims database...
  7. ncbi Differences in baseline characteristics between patients prescribed sitagliptin versus exenatide based on a US electronic medical record database
    Qiaoyi Zhang
    Global Health Outcomes, Merck Sharp and Dohme Corp, One Merck Drive, Whitehouse Station, NJ 08889 0100, USA
    Adv Ther 27:223-32. 2010
    ..This study examined differences in baseline characteristics between patients with type 2 diabetes initiating sitagliptin vs. exenatide treatment in clinical practice settings in the US...
  8. ncbi Treatment and outcomes in patients with asthma and allergic rhinitis in the United kingdom
    Qiaoyi Zhang
    Merck and Co, Whitehouse Station, NJ 08889 0100, USA
    Int Arch Allergy Immunol 142:318-28. 2007
    ..Since allergic rhinitis in asthma patients is associated with worse asthma control, the treatment of the comorbid condition may improve outcomes...
  9. doi Glycemic effectiveness and medication adherence with fixed-dose combination or coadministered dual therapy of antihyperglycemic regimens: a meta-analysis
    Steven Han
    Merck Sharp and Dohme Corp, Whitehouse Station, NJ, USA
    Curr Med Res Opin 28:969-77. 2012
    ..To compare effects of fixed-dosed combinations (FDCs) and coadministered dual therapy (CDT) of antihyperglycemic agents on glycemic control (i.e., HbA(1c)) and medication adherence...
  10. pmc Physician reasons for nonpharmacologic treatment of hyperglycemia in older patients newly diagnosed with type 2 diabetes mellitus
    Elizabeth Marrett
    Global Health Outcomes, WS2E85, 1 Merck Drive, Whitehouse Station, NJ, 08889, USA
    Diabetes Ther 3:5. 2012
    ..To identify reasons why primary care physicians (PCPs) do not treat older patients newly diagnosed with type 2 diabetes mellitus (T2DM) with antihyperglycemic agents following diagnosis...
  11. pmc Limitations of real-world treatment with atorvastatin monotherapy for lowering LDL-C in high-risk cardiovascular patients in the US
    Elizabeth Marrett
    Merck and Co, Inc, Whitehouse Station, NJ, USA
    Vasc Health Risk Manag 10:237-46. 2014
    ..This study assessed attainment of guideline-recommended LDL-C levels in high-risk CVD patients treated with atorvastatin monotherapy...
  12. doi Suboptimal persistence with inhaled corticosteroid monotherapy among children with persistent asthma in the UK
    Qiaoyi Zhang
    Global Health Outcomes, Merck and Co, Inc, Whitehouse Station, NJ, USA
    Prim Care Respir J 20:97-101. 2011
    ..Long-term studies indicate that adherence to asthma controller therapy decreases over time, and persistence with therapy may be poor...
  13. doi Maternal anaemia and preterm birth: a prospective cohort study
    Qiaoyi Zhang
    Merck and Co, Inc, Whitehouse Station, NJ, USA
    Int J Epidemiol 38:1380-9. 2009
    ..We examined if maternal anaemia exposure both within and across trimesters during gestation is associated with preterm birth...